411 related articles for article (PubMed ID: 12479597)
1. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
Crawford J
Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
[TBL] [Abstract][Full Text] [Related]
2. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Holmes FA; Jones SE; O'Shaughnessy J; Vukelja S; George T; Savin M; Richards D; Glaspy J; Meza L; Cohen G; Dhami M; Budman DR; Hackett J; Brassard M; Yang BB; Liang BC
Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
[TBL] [Abstract][Full Text] [Related]
3. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
4. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
5. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
[TBL] [Abstract][Full Text] [Related]
6. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
Molineux G
Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
[TBL] [Abstract][Full Text] [Related]
7. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
8. Pegfilgrastim.
Curran MP; Goa KL
Drugs; 2002; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
[TBL] [Abstract][Full Text] [Related]
9. Pegfilgrastim for chemotherapy-induced neutropenia.
Bedell C
Clin J Oncol Nurs; 2003; 7(1):55-6, 63-4. PubMed ID: 12629935
[TBL] [Abstract][Full Text] [Related]
10. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.
Yang BB; Savin MA; Green M
Chemotherapy; 2012; 58(5):387-98. PubMed ID: 23296266
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.
Frampton JE; Keating GM
BioDrugs; 2005; 19(6):405-7. PubMed ID: 16392893
[TBL] [Abstract][Full Text] [Related]
12. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).
Molineux G
Curr Pharm Des; 2004; 10(11):1235-44. PubMed ID: 15078138
[TBL] [Abstract][Full Text] [Related]
13. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
Biganzoli L; Untch M; Skacel T; Pico JL
Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
[TBL] [Abstract][Full Text] [Related]
14. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB; Kido A
Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
[TBL] [Abstract][Full Text] [Related]
16. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
[TBL] [Abstract][Full Text] [Related]
17. Pegfilgrastim.
Willis F; Pettengell R
Expert Opin Biol Ther; 2002 Dec; 2(8):985-92. PubMed ID: 12517276
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
Crawford J
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
[TBL] [Abstract][Full Text] [Related]
19. Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor.
Mucenski JW; Shogan JE
J Manag Care Pharm; 2003; 9(2 Suppl):10-4. PubMed ID: 14613339
[TBL] [Abstract][Full Text] [Related]
20. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma.
Wendelin G; Lackner H; Schwinger W; Sovinz P; Urban C
J Pediatr Hematol Oncol; 2005 Aug; 27(8):449-51. PubMed ID: 16096530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
